옵션 체인은 다양한 행사가격과 만기일에 대한 Alignment Healthcare의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Alignment Healthcare에 대한 시장 심리를 평가합니다..

Alignment Healthcare (NASDAQ:ALHC) 주식, 옵션 체인

Alignment Healthcare

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

Mid Cap

News

Movers

ALHC

TWST

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 1. 쾨르 마이닝(NYSE:CDE)의 주식은 36.59% 상승했다. 이 회사는 네바다주에 확장된 로체스터(Rochester) 은-금 광산의 처리량 추세가 긍정적이라고 보고했다.

쾨르 마이닝, 뉴 골드 및 RH는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 8일-9월 14일)

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare Inc

Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) demand for <a target="_blank" href="https://www.benzinga.com/topic/semiconductors" rel="noreferrer noopener">advanced packaging from</a> Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) remains robust despite its evolving technology requirements, Reuters cites Nvidia chief Jensen Huang in response to its order cut plans.
Huang voiced plans to employ Chip-On-Wafer-On-Substrate-L&nbsp;(CoWoS-L) for its Blackwell transition and gradually ramp up capacity into the technology despite depending on CowoS-S for its Hopper artificial intelligence (AI) chip.
For context, Nvidia has relied mainly on CoWoS-S to combine its AI chips.
Nvidia&#8217;s Blackwell AI chip leverages Taiwan Semiconductor&#8217;s CoWoS advanced packaging technology.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43022654/taiwan-semiconductor-q4-earnings-3nm-and-5nm-nodes-lead-topline-growth-expands-margins-issues-strong-q1-outlook" rel="noreferrer noopener">Taiwan Semiconductor Q4 Earnings: 3nm and 5nm Nodes Lead Topline Growth, Expands Margins, Issues Strong Q1 Outlook</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16122503/newplot-5.png" alt="" class="wp-image-737361" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16122503/newplot-5.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16122503/newplot-5-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Recently, TF International Securities analyst Ming-Chi Kuo and the Taiwan media flagged Nvidia&#8217;s shift to CoWoS-L, which is likely affecting the Taiwanese chipmaker&#8217;s CowoS-S revenue.
Due to capacity constraints, packaging has remained a bottleneck for the Blackwell chips, <a target="_blank" href="https://www.benzinga.com/news/24/05/39060364/nvidia-accelerates-ai-chip-production-with-new-packaging-tech-to-meet-soaring-demand" rel="noreferrer noopener">prompting Nvidia to</a> employ Fan-Out Panel Level Packaging (FOPLP) technology for its GB200 AI server chips.
Still, Huang said that the advanced packaging capacity was &#8220;probably four times&#8221; the amount available less than two years ago.
<a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41706702/nvidia-supplier-tsmc-to-double-advanced-chip-packaging-capacity-as-ai-demand-from-microsoft-amaz" rel="noreferrer noopener">Prior reports indicated</a> Taiwan Semiconductor will likely double its CoWoS production capacity in 2025, with Nvidia likely to occupy over 50% of the capacity.
Despite Taiwan Semiconductor&#8217;s efforts to ramp up production, the demand for advanced packaging continues to exceed supply, prompting it to double its CoWoS production capacity by 2025.
Price Actions: At last check on Thursday, NVDA stock was down 1.52% to $134.18. TSM is up 4.99%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence" target="_blank" rel="noreferrer noopener">Microsoft Launches CoreAI Division: Ex-Meta Exec To Supercharge Copilot And AI Innovations</a></li>
</ul>
Photo via Shutterstock

Tech

Media

NVDA

Nvidia Continues Strong Demand for Taiwan Semiconductor's Advanced Packaging Despite Technology Shifts

Citigroup analyst Steven Enders maintains Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) with a Buy and lowers the price target from $90 to $83.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Dayforce, Lowers Price Target to $83

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 150 points on Thursday.
The Dow traded down 0.27% to 43,106.65 while the NASDAQ fell 0.79% to 19,356.43. The S&amp;P 500 also fell, dropping, 0.28% to 5,933.22.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Utilities shares surged by 2.3% on Thursday.
In trading on Thursday, consumer discretionary shares fell by 1.1%.
Top Headline
On Thursday, Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) reported upbeat earnings for its fourth quarter.
The bank posted fourth-quarter adjusted EPS of $2.22, up from $0.85 a year ago and beating the consensus of $1.70. Net earnings more than doubled from $1.52 billion to $3.7 billion.
The U.S. bank reported fourth-quarter revenue of $16.22 billion, up 26% year over year, beating the consensus of $15.03 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares shot up 102% to $0.6820 after the company announced its Fortel Prostate Specific Antigen Screening Test received approval from the United Arab Emirates Ministry of Health and Prevention.</li>
<li>Shares of DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>)got a boost, surging 26% to $15.53 as the company appointed Simin Ren as Co-CEO and declared a special cash dividend.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares were also up, gaining 19% to $31.88 after the company disclosed a deal to acquire Walmart Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) Advanced Systems and Robotics business.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Leafly Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares dropped 45% to $0.8001 after the company announced it received a Nasdaq desliting notice and will transition to the over-the-counter market.</li>
<li>Shares of Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) were down 34% to $8.70 after the company issued regulatory and business update on EBVALLOTM (tabelecleucel).</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) was down, falling 11% to $1.09 after the company reported preliminary third-quarter revenue of $551 million, down 10% year over year, citing lower volume and competitive market conditions.</li>
</ul>
Commodities In commodity news, oil traded down 1.9% to $78.49 while gold traded up 1.4% at $2,755.10.
Silver traded up 1% to $31.860 on Thursday, while copper rose 1.1% to $4.4350.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 surged 0.98%, Germany's DAX 40 gained 0.39% and France's CAC 40 gained 2.14%. Spain's IBEX 35 Index fell 0.49%, while London's FTSE 100 gained 1.09%.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei 225 gaining 0.33%, China's Shanghai Composite Index gaining 0.28%, Hong Kong's Hang Seng Index climbing 1.23% and India's BSE Sensex rising 0.42%.
Economics
<ul>
<li>U.S. retail sales rose 0.4% month-over-month in December versus a revised 0.8% increase in the previous month and down from market estimates of 0.6%.</li>
<li>U.S. initial jobless claims increased by 14,000 from the previous week to 217,000 in the week ending January 11, compared to market estimates of 210,000.</li>
<li>Import prices increased by 0.1% from the previous month in December, while export prices gained by 0.3% in December.</li>
<li>The Philadelphia Fed Manufacturing Index rose to 44.3 in January compared to a revised reading of -10.9 in the previous month.</li>
<li>The NAHB/Wells Fargo Housing Market Index rose to 47 in January compared to 46 in the prior two months.</li>
<li>U.S. business inventories increased by 0.1% month-over-month in November compared to a revised flat reading in the previous month.</li>
<li>U.S. natural-gas stocks fell 258 billion cubic feet during the week ending Jan. 1, the EIA said.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43025282/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATRA

BMRA

DOYU

LFLY

PSNY

Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates

Citigroup analyst Steven Enders maintains Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) with a Neutral and raises the price target from $16 to $20.

ASAN

Citigroup Maintains Neutral on Asana, Raises Price Target to $20

The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading slightly lower on Thursday.</a>
Yesterday, the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42999464/bny-exceeds-q4-targets-with-strong-revenue-and-margins-showing-confidence-in-its-strategy" rel="noreferrer noopener">fourth-quarter 2024 results</a>. The finance behemoth reported fourth-quarter adjusted earnings per share of $1.72 (+33% YoY),&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the street view of $1.56.</a>
Here are some analysts&#8217; take on the stock:
<ul>
<li>Goldman Sachs analyst Alexander Blostein reiterated the Buy rating on the stock, raising the <a href="https://www.benzinga.com/quote/BK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast to $96 from $91.</a></li>
<li>Keefe, Bruyette &amp; Woods analyst David Konrad maintained the Outperform rating on the stock, with a price forecast of $96.</li>
<li>Truist Securities analyst David Smith maintained the Buy rating, with a price forecast of $91.</li>
</ul>
Goldman Sachs: The analyst sees the company&#8217;s 2025 and medium-term targets suggest a strong 10%+ EPS growth, not fully reflected in the stock&#8217;s 11X 2025 P/E.
Per the analyst, the management team is gaining credibility, which could lead to increased investor confidence and higher valuations.
Blostein writes that key factors supporting the Buy rating include better NII growth, which is 6% higher than consensus due to improved deposit levels, positive fee income growth driven by a differentiated business mix, and continued expense management with 1% &#8211; 2% growth expected in 2025.
The analyst sees potential for sustained positive operating leverage and appreciates the growing investor recognition of the fee growth potential. EPS estimates for 2025, 2026, and 2027 have been raised by the analyst to $7.09, $8.15, and $9.26, from $6.79, $7.81, and $8.79 respectively, reflecting higher growth compared to consensus.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43031980/big-banks-continue-to-beat-q4-earnings-financial-etf-takes-breather" rel="noreferrer noopener">Big Banks Continue To Beat Q4 Earnings As Financial ETF Takes A Breather</a>
Keefe, Bruyette &amp; Woods: The analyst raised 2025 and 2026 EPS estimates by $0.15 to $6.80 and $0.10 to $7.65, respectively, due to improved deposit behavior and higher NII expectations.
Per Konrad, while deposits are expected to moderate in 2025, the strong results in the second half of 2024 are projected to drive 5% NII growth in 2025.
Despite recent outperformance, the analyst sees a significant upside as the stock is trading in line with peers.
Truist Securities: The outlook for the year is neutral, with fees expected to rise YoY, the analyst writes.
Per Smith, a 5% increase in markets could add ~$70 million in annualized fees.
BNY plans to invest $0.5 billion, double its 2024 investment. The effective tax rate is expected to be 22% &#8211; 23%.
The analyst writes, by the first quarter of 2025, over half of the company&#8217;s workforce will operate on the platform model, with plans for 85% by year-end.
Price Action: BK shares are trading lower by 0.69% to $81.47 at last check Thursday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43027744/retail-sales-slow-jobless-claims-rise-is-us-consumer-loosing-steam" target="_blank" rel="noreferrer noopener">Retail Sales Disappoint, Jobless Claims Rise: Is US Consumer Losing Steam?</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Reiteration

General

Bank Of New York Mellon's Differentiated Business Mix And NII Growth Signal Upside: Goldman Sachs

Maxim Group analyst Jason McCarthy maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and raises the price target from $8 to $15.

OSTX

Maxim Group Maintains Buy on OS Therapies, Raises Price Target to $15

GLNCY

Rio Tinto, Glencore Are Said To Discuss Potential Combination

Kanavos Inc. has announced a strategic partnership with Graphwise, a global leader in semantic AI technologies, and HomeLab, a prominent biotech accelerator based at UC San Diego, to develop the Cannabis Knowledge Graph. 
Graphwise, known for its expertise in creating advanced knowledge graph solutions, brings a deep understanding of data organization and AI-powered insights, making it an ideal partner for this initiative. HomeLab, a key player in fostering biotech innovation, has supported more than 50 startups and helped raise more than $1.5 billion in funding, positioning it as a trusted hub for life sciences innovation. 
The Cannabis Knowledge Graph, aimed at providing patients and healthcare providers with accessible, evidence-based insights into cannabinoid therapies, was unveiled this week in San Francisco, coinciding with the J.P. Morgan Healthcare Conference taking place in the city. This announcement represents a significant step toward addressing the fragmented state of cannabis research and empowering more informed treatment decisions.
<h2 class="wp-block-heading">A New Approach To Cannabis Medicine</h2>
The Cannabis Knowledge Graph is still under development, but its goals are clear: to provide cannabis patients a unified source to discover scientific evidenced based therapeutics empowering personalized actionable decisions, consolidate clinical trials, preclinical research and real-world evidence into a unified resource. By leveraging Graphwise's Semantic AI technology, Kanavos aims to create a tool that provides actionable, personalized insights to patients and providers navigating cannabinoid-based medicine.
At its core, a knowledge graph is a data structure that organizes information by mapping relationships between entities. In the context of cannabis medicine, this means connecting diverse data sources—such as scientific evidence-based research with provenance, clinical trials, and patient outcomes—to reveal meaningful patterns and actionable insights. Unlike traditional databases, which simply store information, a Semantic AI knowledge graph enables AI systems to interpret and understand the meaning behind human language, concepts and data. This allows for a deeper understanding of how data points are interconnected, making it particularly valuable for complex fields like healthcare.
"This partnership with Graphwise marks a significant milestone for patients seeking to leverage the therapeutic potential of cannabinoids," said Dr. Deborah McGuinness, chief knowledge officer at Kanavos. "By combining our deep domain expertise with Graphwise's leading-edge technology, we are empowering individuals with the knowledge and insights they need to make informed healthcare decisions."
<h2 class="wp-block-heading">Addressing Critical Industry Challenges</h2>
The fragmented nature of cannabis research has long been a challenge for patients and providers. The Cannabis Knowledge Graph seeks to address this by organizing and contextualizing data, enabling users to compare therapeutic options and make more informed decisions. Unlike generative AI tools, the platform focuses on understanding relationships in data to deliver meaningful insights.
"By connecting disparate data sources – from Open LinkedLife Data to 80 million research publications, clinical trials to real-world evidence with provenance – we can unlock invaluable insights and empower patients with the information they need to make informed healthcare decisions," said Antanas Kiryakov, president of Graphwise.
<h2 class="wp-block-heading">The Road Ahead</h2>
Kanavos&#8217; partnerships include licenses for adult-use cannabis and DEA Schedule 1 drug manufacturing for research and development, positioning the company to explore novel therapeutic applications for cannabinoids as the Cannabis Knowledge Graph takes shape. This initiative is part of a broader trend of applying advanced semantic AI technologies to life sciences, healthcare and the wellness industries. The goal is to legitimize and expand the use of cannabinoids in therapeutic settings through rigorous data integration and actionable insights.
By building this platform, Kanavos is contributing to the broader adoption of data-driven solutions in healthcare. The company's collaborations with Graphwise and HomeLab aim to address challenges in cannabis research and facilitate advancements in cannabinoid-based medicine.
Cover image made with AI

Cannabis

Can AI Solve Cannabis Medicine's Data Problem? New Tech Initiative Aims To Streamline Research And Treatments

Maxim Group initiates coverage on Rezolve AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) with a Buy rating and announces Price Target of $10.

Initiation

RZLV

Maxim Group Initiates Coverage On Rezolve AI with Buy Rating, Announces Price Target of $10

WIIM

KPLT

Katapult shares are trading higher after the company provided Q4 business updates and key financial metrics.

Macro Economic Events

Economics

Federal Reserve

'Chicago Fed President Austan Goolsbee says he feels more comfortable that the labor market is stabilizing' -WSJ

Leafly Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares are trading lower by 49% to 73 cents Thursday afternoon after the company announced it received a Nasdaq <a href="https://www.benzinga.com/pressreleases/25/01/b43027895/leafly-announces-receipt-of-notice-of-delisting-from-nasdaq-and-transition-to-over-the-counter-mar">delisting notice</a> and will transition to the over-the-counter market.
What Else: The delisting stems from the company&#8217;s failure to meet minimum financial requirements, including $500,000 in net income from continuing operations, as outlined in Nasdaq Listing Rule 5550(b). Trading of Leafly's stock and warrants will be suspended starting January 17.
The securities are expected to trade on the OTC Pink Open Market under the symbols &#8220;LFLY&#8221; and &#8220;LFLYW&#8221; on the same day.
While this shift won&#8217;t impact the company's operations, Leafly cautions that continued market trading of its securities is not guaranteed on over-the-counter markets or elsewhere.
Read Also: <a href="https://www.benzinga.com/general/travel/25/01/43036258/polar-vortex-brings-winters-coldest-air-for-trumps-inauguration-day-what-it-means-for-utilities-retailers-energy-stocks">Polar Vortex Brings Winter&#8217;s Coldest Air For Trump&#8217;s Inauguration Day: What It Means For Utilities, Retailers, Energy Stocks</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LFLY has a 52-week high of $4.92 and a 52-week low of $0.70.

Why Leafly (LFLY) Stock Is Down 49% Today

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) submitted by Vanda Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) for Tradipitant for symptoms in gastroparesis.
The <a target="_blank" href="https://public-inspection.federalregister.gov/2025-01027.pdf" rel="noreferrer noopener">notice</a> offers Vanda an opportunity to request a hearing on the matter.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41692641/over-200-stock-upside-vanda-pharmaceuticals-undervalued-with-robust-portfolio-and-p" rel="noreferrer noopener">Over 200% Stock Upside &#8211; Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst</a>
In September, the FDA issued a Complete Response Letter to the company. The agency disregarded the evidence provided and instead suggested that Vanda conduct additional studies with a design and duration inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding and natural <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40941051/fda-strikes-off-vanda-pharmaceuticals-tradipitant-for-stomach-paralysis-asks-for-additional-studi" rel="noreferrer noopener">course of the disorder</a>.&nbsp;
Last week, Vanda Pharmaceuticals wrote a letter to the FDA Commissioner highlighting faulty <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42886503/vandas-letter-to-fda-commissioner-highlights-faulty-gastroparesis-nda-review" rel="noreferrer noopener">gastroparesis NDA review</a>.
The FDA identified:
<ul>
<li>In the 3301 Phase 3 Study (Group 1), the drug did not show a statistically significant improvement over placebo for nausea severity or other gastroparesis symptoms. Secondary measures results also lacked meaningful differences and sometimes even favored the placebo.</li>
<li>2301 Phase 2 Study: While it showed significant results for nausea at Week 4, the study had methodological flaws and inadequate data handling, reducing the reliability of its findings. Additionally, Study 3301 failed to confirm the results of Study 2301.</li>
<li>Confirmatory Evidence: Post hoc analyses and pooled data from the studies were insufficient to support efficacy claims. Other sources, such as open-label studies and unrelated motion sickness trials, could not confirm the drug&#8217;s effectiveness.</li>
<li>Safety: Data from trials were limited to 12 weeks, which is inadequate for a chronic condition like gastroparesis that requires long-term treatment. Animal and lab studies did not provide enough information to assess long-term safety risks for humans.</li>
</ul>
The FDA recommended conducting two new, well-designed clinical trials in adults with idiopathic or diabetic gastroparesis to address the deficiencies and perform a long-term toxicity study in a non-rodent species.
Vanda could either resubmit the application addressing all deficiencies, withdraw the application, or request a hearing.
In November 2024, Vanda received a formal notice of opportunity for a hearing.
Price Action: VNDA stock is down 2.45% at $4.34 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business" target="_blank" rel="noreferrer noopener">Chemical Company DuPont Accelerates Electronics Business Separation, Retains Water Business</a></li>
</ul>

Biotech

Health Care

VNDA

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate

Financial giants have made a conspicuous bullish move on Red Cat Hldgs. Our analysis of options history for Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) revealed 10 unusual trades.
Delving into the details, we found 60% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $189,895, and 6 were calls, valued at $259,200.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $9.0 and $15.0 for Red Cat Hldgs, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Red Cat Hldgs options trades today is 1238.38 with a total volume of 3,507.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Red Cat Hldgs's big money trades within a strike price range of $9.0 to $15.0 over the last 30 days.
<h3>Red Cat Hldgs Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737053158_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.5</td>
<td>$1.3</td>
<td>$1.5</td>
<td>$9.00</td>
<td>$75.0K</td>
<td>635</td>
<td>666</td>
</tr>
<tr>
<td>RCAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.6</td>
<td>$0.5</td>
<td>$0.59</td>
<td>$11.00</td>
<td>$70.8K</td>
<td>2.2K</td>
<td>1.4K</td>
</tr>
<tr>
<td>RCAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.85</td>
<td>$2.7</td>
<td>$2.85</td>
<td>$10.00</td>
<td>$57.0K</td>
<td>1.7K</td>
<td>222</td>
</tr>
<tr>
<td>RCAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$4.7</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$15.00</td>
<td>$45.5K</td>
<td>198</td>
<td>0</td>
</tr>
<tr>
<td>RCAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.8</td>
<td>$4.3</td>
<td>$4.4</td>
<td>$15.00</td>
<td>$44.0K</td>
<td>986</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About Red Cat Hldgs</h3>
Red Cat Holdings Inc is a military technology company that integrates robotic hardware and software to provide critical situational awareness and actionable intelligence to on-the-ground warfighters and battlefield commanders. Its mission is to enhance the effectiveness and safety of military operations domestically and globally. Red Cat's suite of solutions includes Teal Drones, developer of the Golden Eagle, a small unmanned system with the highest resolution imaging for night-time operations, and Skypersonic, a provider of unmanned aircraft for interior spaces and other dangerous environments.
After a thorough review of the options trading surrounding Red Cat Hldgs, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Red Cat Hldgs's Current Market Status</h3>
<ul>
<li>With a trading volume of 9,335,069, the price of RCAT is down by -3.99%, reaching $10.47.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 60 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Red Cat Hldgs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

RCAT

Looking At Red Cat Hldgs's Recent Unusual Options Activity

High-rolling investors have positioned themselves bullish on Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in OKLO often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 14 options trades for Oklo. This is not a typical pattern.
The sentiment among these major traders is split, with 57% bullish and 28% bearish. Among all the options we identified, there was one put, amounting to $25,110, and 13 calls, totaling $2,410,355.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $22.5 to $30.0 for Oklo during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Oklo stands at 2091.4, with a total volume reaching 7,305.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Oklo, situated within the strike price corridor from $22.5 to $30.0, throughout the last 30 days.
<h3>Oklo Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737053153_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.1</td>
<td>$4.85</td>
<td>$4.89</td>
<td>$22.50</td>
<td>$1.7M</td>
<td>5.0K</td>
<td>3.9K</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.2</td>
<td>$2.91</td>
<td>$2.93</td>
<td>$28.00</td>
<td>$145.1K</td>
<td>2.1K</td>
<td>500</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.95</td>
<td>$4.7</td>
<td>$4.76</td>
<td>$22.50</td>
<td>$142.8K</td>
<td>5.0K</td>
<td>412</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.75</td>
<td>$7.4</td>
<td>$7.8</td>
<td>$30.00</td>
<td>$77.9K</td>
<td>1.5K</td>
<td>4</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.0</td>
<td>$4.65</td>
<td>$4.75</td>
<td>$22.50</td>
<td>$52.2K</td>
<td>5.0K</td>
<td>112</td>
</tr>
</tbody>
</table>

<h3>About Oklo</h3>
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
Following our analysis of the options activities associated with Oklo, we pivot to a closer look at the company's own performance.
<h3>Where Is Oklo Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 7,507,967, the OKLO's price is down by -0.12%, now at $24.14. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>Professional Analyst Ratings for Oklo</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $28.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $26. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Oklo, targeting a price of $31. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Oklo, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

OKLO

A Closer Look at Oklo's Options Market Dynamics

Financial giants have made a conspicuous bearish move on IBM. Our analysis of options history for IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) revealed 15 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 53% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $431,210, and 6 were calls, valued at $465,157.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $180.0 to $250.0 for IBM over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for IBM's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across IBM's significant trades, within a strike price range of $180.0 to $250.0, over the past month.
<h3>IBM Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737053148_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.1</td>
<td>$2.0</td>
<td>$2.0</td>
<td>$250.00</td>
<td>$154.2K</td>
<td>10.3K</td>
<td align="right">775</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$39.35</td>
<td>$37.95</td>
<td>$38.67</td>
<td>$180.00</td>
<td>$83.9K</td>
<td>3</td>
<td align="right">22</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$38.35</td>
<td>$37.25</td>
<td>$37.6</td>
<td>$180.00</td>
<td>$82.7K</td>
<td>2.2K</td>
<td align="right">22</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$19.8</td>
<td>$19.5</td>
<td>$19.8</td>
<td>$200.00</td>
<td>$79.1K</td>
<td>2.4K</td>
<td align="right">55</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$25.5</td>
<td>$24.8</td>
<td>$24.8</td>
<td>$240.00</td>
<td>$52.0K</td>
<td>932</td>
<td align="right">21</td>
</tr>
</tbody>
</table>

<h3>About IBM</h3>
IBM looks to be a part of every aspect of an enterprise's IT needs. The company sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 350,000 people. The company has a robust roster of 80,000 business partners to service 5,200 clients, which includes 95% of all Fortune 500. While IBM is a B2B company, IBM's outward impact is substantial. For example, IBM manages 90% of all credit card transactions globally and is responsible for 50% of all wireless connections with the world.
After a thorough review of the options trading surrounding IBM, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of IBM</h3>
<ul>
<li>With a volume of 1,353,310, the price of IBM is up 0.41% at $220.94. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 13 days.</li>
</ul>
<h3>What Analysts Are Saying About IBM</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $187.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from UBS has decided to maintain their Sell rating on IBM, which currently sits at a price target of $160. 
&#x2A; An analyst from Bernstein persists with their Market Perform rating on IBM, maintaining a target price of $215. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest IBM options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

A Closer Look at IBM's Options Market Dynamics

"It&#8217;s tough to make predictions, especially about the future." … Yogi Berra
My firm, <a href="http://lcmcapital.com" target="_blank" rel="noreferrer noopener">LCM Capital Management</a>, has always despised the New Year since our firm's inception more than 25 years ago.  The reason: it's when our financial industry parades out their analysts, strategists, and economists, aka "experts", and tell the investing population what they believe is going to happen in the coming year.  Which stocks or sectors to own or not to own, what will happen with the economy and interest rates?  The problem is, they are almost always wrong and yet investors seem to take their guesses, and that's all they are, as Gospel.  Do your portfolio a favor, as our clients tend to do, and turn-off CNBC and all the talking heads on TV this time of year.  
These "experts," armed with complex models, historical data, and sophisticated analytics can play a role in shaping public policy and guiding business strategies and forming investment decisions. &nbsp;They project confidence in their ability to predict the future and yet, year after year, economic forecasts fall wide of the mark.
So why are economists, analysts and market strategists so often wrong, and what does this mean for those who invest based on their predictions, particularly investors nearing retirement?
Economic forecasting is inherently complex because economies are not closed systems. &nbsp;Think about our world today and how inter-connected it all is. &nbsp;The world economies are influenced by countless interdependent factors, many of which are unpredictable.&nbsp; Natural disasters, geopolitical tensions, technological disruptions, and consumer behavior, for example, all can upend even the most carefully constructed economic models.
These "experts" typically rely on historical data to project future trends. &nbsp;While history does provide valuable context, it can also be very misleading. &nbsp;As Nobel laureate Daniel Kahneman once said, &#8220;The idea that the future is unpredictable is undermined every day by the ease with which the past is explained.&#8221;
I am sure at some point you have either been told or read the following, "past performance is no guarantee of future results" and yet we often forget this.
Recent history offers several glaring examples of economists getting it wrong. &nbsp;These missteps underscore the inherent challenges of economic forecasting and the potential pitfalls of relying on predictions.
The Federal Reserve and Inflation (2021–2022) &#8211; In 2021, Federal Reserve Chair Jerome Powell famously described rising inflation as &#8220;transitory.&#8221;&nbsp; The Fed anticipated that inflationary pressures, driven by supply chain disruptions and pandemic-related stimulus, would subside quickly. &nbsp;Instead, inflation surged to multi-decade highs, forcing the Fed into its most aggressive interest rate hiking cycle in 40 years. &nbsp;At the end, when the Fed was finally done raising rates, Fed Chairman Powell said, "We now understand better how little we understand about inflation."&nbsp;
This miscalculation wasn't just a simple slip-up—it had real, lasting consequences. &nbsp;Businesses, consumers, and investors made decisions based on the Fed's assurances, only to face unexpected economic challenges as inflation persisted. &nbsp;And think about this: there are more than 400 PhD economists employed by the Federal Reserve Board and they were dead wrong as to how high, how long, and how severe inflation would be and how deep the subsequent recession would last. I am sure these are some of the brightest minds in our country and yet, even with all of the data and information at their fingertips, they were wrong. However, common sense and the lessons of the past led many "experts" to believe that the inverted yield curve caused by the Fed's unprecedented monetary tightening signaled a recession ahead.&nbsp; They were incorrect as well. &nbsp;So how possibly can someone, for example say Jim Cramer, predict what will happen this year or the next? &nbsp;He can't, and while I find Mr. Cramer sometimes entertaining, he is a journalist first and foremost.
Another recent example, as the world emerged from the COVID-19 pandemic, many economists predicted a sluggish, protracted recovery. &nbsp;Instead, global economies bounced back faster than anyone expected, thanks to an unprecedented wave of fiscal and monetary stimulus. &nbsp;Consumer spending surged, and labor markets tightened, defying predictions of a drawn-out downturn. &nbsp;During the pandemic, as tech stocks soared, many economists and analysts warned of an impending collapse akin to the dot-com bubble of the early 2000s. &nbsp;Sure, some overvalued companies took a hit, but the sector turned out to be much more resilient than expected and the S&amp;P 500 rose by over 18% that year, way above the historical average rate of return of 7.71% when adjusted for inflation and including dividends.
But let's cut these "experts" some slack, after all they are all human beings and as a result, are just as prone to mental shortcuts and biases as the rest of us. &nbsp;Confirmation bias, which is the tendency of people to favor information that confirms or strengthens their beliefs or values, is difficult to dislodge once affirmed and can lead them to favor data that supports their existing theories. &nbsp;Overconfidence bias can result in undue certainty about uncertain outcomes. &nbsp;Just to be clear, we are not believers that AI or computers etc. can do any better predicting the future. &nbsp;They can't. &nbsp;They all use historical data to help them formulate their best guesses and always remember, in the end, it is still just a guess.
So what should investors do?&nbsp; First, your New Years resolution should be to turn off CBNC or whatever your favored business channel is, or at the very least, mute it! &nbsp;By spreading your investments across asset classes, sectors, and geographies, you can help reduce your exposure to any single economic or financial outcome. &nbsp;A well-diversified portfolio can help mitigate the risks associated with inaccurate forecasts. Maintaining a long-term outlook can help you weather periods of volatility and uncertainty. &nbsp;Lastly, control what you can control. &nbsp;While you can't control inflation rates or GDP growth, you can control your TV's volume, and the fees you pay, as well as your savings rate, spending habits, and investment discipline. &nbsp;Prioritizing these factors can have a more significant impact on your financial future than any forecast. &nbsp;By realizing that the future is uncertain and focusing on what you can control, you'll be better equipped to navigate the ever-changing economic landscape as well as become a happier person.
In the end, realize that these "experts" are likely bright people with plenty of information and research available to them. &nbsp;However, they are only making an educated guess at best because if they actually knew what was going to happen, they would already be retired. &nbsp;The late founder of Vanguard, Jack Bogle, once said, "Research has no net value…no one has been able to validate that stock research has any value. If research had value, it would be called proprietary and therefore would be extremely expensive and unavailable for public viewing"
Therefore, stay informed about economic trends, but approach all predictions with a healthy dose of cynicism. &nbsp;Too often, well-informed economists' predictions are far from accurate or reliable. &nbsp;The complexity of global economies, combined with the unpredictability of human behavior and external shocks, makes accurate forecasting a near-impossible task.
Remember what the famed economist John Kenneth Galbraith once said, "There are two kinds of forecasters: those who don't know, and those who don't know they don't know."
There is a better way.
<a href="http://lcmcapital.com">LCM Capital Management</a>

Financial Advisors

Why Economists Are Always Wrong

FARO

FARO Technologies shares are trading higher after Needham raised its price target on the stock from $26 to $34.

TIXT

TELUS International shares are trading higher after Stifel initiated coverage on the stock with a Buy rating and announced a price target of $5.

NGVT

Ingevity shares are trading higher after the company announced preliminary Q4 and FY24 financial results. Additionally, the company announced it's exploring strategic options for the performance chemical segment of the business.

Stephens upgraded Alignment Healthcare (ALHC) to Overweight from Equal Weight with a price target of $17, up from $13. Alignment's competitive adva...

Alignment Healthcare upgraded to Overweight from Equal Weight at Stephens

Unusual total active option classes on open include: Alignment Healthcare (ALHC), Navitas Semiconductor (NVTS), JetBlue (JBLU), AES Corp. (AES), Pl...

Unusually active option classes on open December 4th

Stephens analysts presented the firm's 2025 Best Ideas list, which includes Valley National (VLY), CoStar Group (CSGP), Castle Biosciences (CSTL), ...

Stephens lays out 21 Best Ideas for 2025

Alignment Healthcare ( ($ALHC) ) just unveiled an announcement. Alignment Healthcare announced the promotion of Dawn Maroney to President, where sh...

Alignment Healthcare Promotes Maroney Amidst Strong Membership Growth

Alignment Healthcare sees 225K-231K health plan members as of year-end

In a report released yesterday, Michael Craig Jones from Stifel Nicolaus maintained a Buy rating on Alignment Healthcare (ALHC – Research Report), ...

Alignment Healthcare: Strategic Growth and Competitive Edge Justify Buy Rating

Stifel raised the firm's price target on Alignment Healthcare (ALHC) to $16 from $14 and keeps a Buy rating on the shares after the company reporte...

Alignment Healthcare price target raised to $16 from $14 at Stifel

Alignment Healthcare: Growth For Growth's Sake

Next Century Growth Investors Q4 2024 Commentary

Focus On Costs, Regulatory Outlook For Health Insurers In Q4'24 Earnings Season

ADBE

AMZN

ANDE

APPF

ATRO

AVAV

AVGO

AVPT

AXON

AZTA

BMRC

BPMC

BWIN

CAVA

CBLL

CDNA

CGNX

CLOV

CPNG

CSGP

CSTL

CVNA

DXCM

GDYN

GWRE

INOD

JBLU

KIDS

KRUS

LNTH

MATX

MNDY

MPTI

MPWR

MYRG

NSSC

NVTS

ODFL

OSCR

PCTY

PEGA

PNFP

PRVA

PYCR

ROKU

RXST

SAIA

SARO

SIBN

SNOW

SPSC

STKL

TMDX

TNDM

TOST

TSLA

USAP

VERX

VRRM

VRTX

WDAY

WEAV

WING

XMTR

Press Releases

Alignment Health Plan Named a "Best" Medicare Advantage Insurer in North Carolina by U.S. News & World Report for Third Consecutive Year

Alignment Health Plan Named a "Best" Medicare Advantage Insurer in Arizona by U.S. News & World Report

Alignment Health Plan Named a "Best" Medicare Advantage Insurer in California by U.S. News & World Report

Alignment Health Plan Named a "Best" Medicare Advantage Insurer in Nevada by U.S. News & World Report

Alignment Healthcare to Present at UBS Global Healthcare Conference and Stephens Annual Investment Conference

Financing

Alignment Healthcare Announces Private Convertible Senior Notes Transaction

Alignment Health Plan Expands Access to Care in Arizona through Enhanced Agreement with Arizona Priority Care

Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference

UPDATE – Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alignment Healthcare Announces Industry-Leading Membership Growth and Promotion of Dawn Maroney to President

Comments

Alignment Healthcare

Alignment Healthcare (ALHC) 옵션

Alignment Healthcare (NASDAQ:ALHC) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌